O Shaughnessy Asset Management LLC Has $2.13 Million Holdings in Horizon Therapeutics PLC (HZNP)
O Shaughnessy Asset Management LLC raised its stake in Horizon Therapeutics PLC (NASDAQ:HZNP) by 299.5% during the 1st quarter, Holdings Channel reports. The firm owned 80,854 shares of the biopharmaceutical company’s stock after buying an additional 60,617 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Horizon Therapeutics were worth $2,127,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Swiss National Bank lifted its holdings in shares of Horizon Therapeutics by 3.7% during the first quarter. Swiss National Bank now owns 305,456 shares of the biopharmaceutical company’s stock worth $8,073,000 after purchasing an additional 10,800 shares during the period. Cigna Investments Inc. New acquired a new stake in shares of Horizon Therapeutics during the first quarter worth about $201,000. Envestnet Asset Management Inc. lifted its holdings in Horizon Therapeutics by 7.8% in the first quarter. Envestnet Asset Management Inc. now owns 80,019 shares of the biopharmaceutical company’s stock valued at $2,115,000 after acquiring an additional 5,812 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in Horizon Therapeutics by 61.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 83,848 shares of the biopharmaceutical company’s stock valued at $1,732,000 after acquiring an additional 31,848 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in Horizon Therapeutics by 15.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,576 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 467 shares during the period. Institutional investors own 87.79% of the company’s stock.
A number of research analysts have issued reports on the company. Piper Jaffray Companies set a $33.00 price target on Horizon Therapeutics and gave the company a “buy” rating in a report on Thursday, April 4th. Jefferies Financial Group boosted their price target on Horizon Therapeutics to $34.00 and gave the company a “buy” rating in a report on Friday, March 1st. Cantor Fitzgerald boosted their price target on Horizon Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Mizuho set a $27.00 price target on Horizon Therapeutics and gave the company a “hold” rating in a report on Wednesday, May 8th. Finally, Zacks Investment Research raised Horizon Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 8th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $30.83.
Horizon Therapeutics (NASDAQ:HZNP) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.20. The business had revenue of $280.00 million during the quarter, compared to analysts’ expectations of $238.35 million. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The business’s revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 earnings per share. As a group, equities research analysts anticipate that Horizon Therapeutics PLC will post 1.63 EPS for the current year.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: Closed-End Mutual Funds
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.